Research Developments in Atopic Dermatitis

To participate in this activity, please:

Log in Sign Up

Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice. They also discuss new evidence related to the burden of disease experienced by patients and caregivers and intriguing evidence pointing to the heterogeneity of atopic dermatitis.

This program is also available as a podcast.  Download from Spotify or Google Podcasts

Course Credit:

1.75 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2020-08-31
Closes: 2021-10-19

Target Audience:

This activity is intended for dermatologists, pediatric dermatologists, allergists, and other clinicians who manage patients with atopic dermatitis.

This activity is supported by an independent educational grant from Pfizer Inc.
Complete CME Details

    Presenting Faculty

  • Steven R. Feldman, MD, PhD

    Professor of Dermatology, Pathology, and Social Sciences & Health Policy
    Wake Forest University Health Sciences
    Winston-Salem, North Carolina

  • Alan B. Fleischer, Jr, MD

    Professor and Residency Program Director
    Department of Dermatology
    University of Cincinnati College of Medicine
    Cincinnati, Ohio

Learning Objectives

  • Summarize the latest research developments in the pharmacologic treatment of atopic dermatitis with new and emerging agents
  • Describe how new data and recommendations can impact clinical practices to improve care
  • Incorporate evidence-based research into clinical practice

Faculty Disclosures

Steven R. Feldman, MD, PhD

Chief Technology Officer: Causa Technologies

Consultant: AbbVie, Advance Medical, Almirall, Alvotech, Amgen, Arcutis, Arena, BMS, Caremark, Celgene, Dermavant, Galderma Laboratories, LP, Gerson, Lehrman Group, Guidepoint Global, Helsinn, Janssen, Kikaku, Leo Pharma Inc, Lilly, Merck & Co, Inc, Mylan, Novartis Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, XenoPort

Founder: Causa Technologies

Grant Support: AbbVie, Amgen, Celgene, Galderma Laboratories, LP, Janssen, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron, Sanofi

Royalties: Informa, UpToDate, Xlibris

Speakers Bureau: AbbVie, Amgen, Celgene, Janssen, Leo Pharma Inc, Lilly, Novartis      Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sun Pharma

Stockholder: Causa Technologies, Medical Quality Enhancement Corporation


Alan B. Fleischer, Jr, MD

Research support

  • Galderma
  • Trevi

· Consultant

  • Boehringer Ingelheim
  • Incyte
  • Qurient
  • Syneos

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.